|
|
|
| home > ebr > Winter 2015 |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review |
|
|
|
|
|
 |
| |
|
|
Editor’s Letter
In light of the Ebola outbreak, Deborah O’Neil reminds us just what our industry is capable of, as well as reflecting on a number of this edition’s features.
|
|
|
|
Human Airway Epithelium
Hold Your Breath
Air-liquid interface culture models can provide a powerful platform in preclinical drug development for various respiratory diseases. Samuel Constant, Song Huang and Ludovic Wiszniewski at Epithelix and Christophe Mas at OncoTheis explore further.
|
|
|
|
|
Fluorinated Pharmaceuticals
Synthesis and Opportunity
As fluorinated active pharmaceutical ingredients continue to be introduced into the marketplace, Graham Sandford at Durham University and Cormac Murphy at University College Dublin examine the technology.
|
|
|
|
|
Molecular Biomarkers
Mental Change
Efforts in the field of mental illness could lead to novel therapeutic targets and the individualisation of patient strategies. Paul C Guest at Cambridge University reflects on how considering schizophrenia as a whole body disease may result in better treatment approaches.
|
|
|
|
Biomanufacturing Strategies
Keep it Flexible
Accinov’s Sylvain Peyrache and Agnes Nagy contemplate the effect biologics are having on the biopharmaceutical industry. With the recent progression of technology, new solutions are allowing companies to implement biomanufacturing strategies far more easily according to regulation requirements and project timelines.
|
|
|
Cell-Based Therapeutics
Heading For Market
Stefanos Theoharis from apceth GmbH maintains that it is imperative to keep in mind the various end-goals when developing cell-based therapeutics. This will position the final product well in the marketplace of tomorrow, and deliver real benefit to patients in need.
|
|
|
Biopharmaceutical Manufacturing
Synthetic Biology
Dominik Schelshorn, Sanda Ljubicic, Imre Berger and Daniel Fitzgerald of Geneva Biotech contemplate the new era of synthetic biology, and how the rapid advance of tools and technologies is changing the way we produce biopharmaceuticals.
|
|
|
|
Case Study: Schistosomiasis
Positive Action
Schistosomiasis is one of the most prevalent – yet often neglected – parasitic diseases. Elly Kourany-Lefoll, Jennifer Keiser and Remco de Vrueh at the Pediatric Praziquantel Consortium explain how a recent collaboration hopes to formulate readily administrable treatments.
|
|
|
Q&A: Vaccine Insight
Developing Immunity
Frost & Sullivan’s Aish Vivekanandan guides EBR through the hurdles of vaccine development and the impact of Ebola, before discussing what we can expect from the next decade of research.
|
|
|
|
Active Immunotherapy
Fighting Fit
Research has shown the potential for targeted immunotherapy in non-infectious diseases, specifi cally in the prevention and management of non-small-cell lung cancer. Bioven’s Erik D’Hondt and Pangaea Biotech’s Jordi Bertran-Alamillo and Jordi Codony-Servat comment on recent clinical trial results.
|
|
|
Radioimmunotherapy
Alpha, Better
Treating cancer is not a one-size-fits-all proposition. Kaushik Dave and Dragan Cicic from Actinium Pharmaceuticals Inc run through the latest developments in radioimmunotherapy and the promising effects of alpha-emitters in reducing cancerous cells.
|
|
|
Oncology Studies
Put to the Test
SMS-oncology’s Lindy Bosch and Raymond Hoffmans look at the components typically comprising a Phase 1 oncology study, describing characteristics such as sponsor types, drugs used, dose levels and patient stratification, as well as overall trial objectives.
|
|
|
|
Event Review: Crystallography
Crystal Clear
Following on from 2014 – the Year of Crystallography –EBR’s Emma Naks reviews photographer Max Alexander’s exhibition, Illuminating Atoms, which captured crystallography experiments in action, as well as displaying portraits of modern day crystallographers
|
|
|
|
Funding Models
Destination Europe
Poul Sørensen and Emil Pot of European Biopharmaceutical Enterprises comment on Europe’s sluggish R&D output, and recommend mobilising investment to encourage innovative entrepreneurship as a means of boosting economic growth.
|
|
|
In Brief
Crouching Tiger
Emile Bellott casts his mind east and asks: will China have multinational pharma companies of its own? And how will they compare to those in Europe and America?
|
|
|
|
Intellectual Property Act
Right of Way
Jasnoop Cheema at Greenaway Scott assesses the UK’s Intellectual Property Act, outlining how the latest changes hope to simplify the current patenting process and encourage growth in the life sciences sector.
|
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
Arcis Biotechnology and Mirnax Biosens sign exclusive license agreement for Arcis sample prep technology
Daresbury, UK, and
Madrid, Spain, 16 July 2019: Arcis Biotechnology (“Arcis”), the nucleic
acid sample preparation solution provider, and Mirnax Biosens (“Mirnax”), the
developer of microRNA (miRNA) biomarkers for clinical diagnostics, today
announced they have signed an exclusive license agreement for use of Arcis
sample preparation and preservation technology.
More info >> |
|
 |
White Papers |
 |
|
Medpace Reference Laboratories establishes state of the art Flow Cytometry techniques for flexible approaches to clinical trials across multiple therapeutic areas.
Medpace
Cytometry is the process of measuring the properties of individual cells. These properties may include gene or protein expression, chemical properties, deoxyribonucleic acid (DNA) content, and various cellular functions. The earliest methods of cytometry relied upon light microscopy for the classification and observation of cells and cellular components. Microscopy permitted direct visual observation of cells for the first time, leading to the classification of cells by morphology and insight into cellular functions. However, the time required for microscopic analysis constrains the number of samples or number of cells in each sample that can be examined. Therefore, the utility of microscopy for analysis of rare cells or in situations where sample throughput is a priority is limited. Flow cytometry was developed largely to improve upon these limitations.
More info >> |
|
 |
Industry Events |
 |
BioPharm America™ 2019—12th Annual International Partnering Conference
11-12 September 2019, Boston Convention and Exhibition Center (BCEC), Boston, MA 02210 USA
BioPharm America™ is a unique partnering event that forms the nexus of discovery and
realization. Startup companies, established biotech and entrepreneurs from academia
attend in search of finance, pharma and development partners. The event format highlights
innovation and promotes new business relationships by bringing dealmakers from the life
science ecosystem together to engage and de-risk the enormous task of drug development.
Life science executives from around the world gather to identify, meet and to enter
into strategic relationships facilitated by partneringONE®, the world’s leading
web-based partnering system. BioPharm America is the only event in North America
based on the same reputable formula as EBD Group’s acclaimed European events
BIO-Europe® and BIO-Europe Spring®. BioPharm America annually attracts 800+ delegates
from over 500 companies who participated in 2,300+ scheduled one-to-one meetings.
BioPharm America is now part of Biotech Week Boston, and together they draw a total
of over 4,500 life science leaders, scientists and innovators.
More info >> |
|
|
